Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
February 23, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)...
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
February 21, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
February 15, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations at the...
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 07, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
January 09, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept...
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
November 29, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of...
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 08, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient Enrollment...